---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-070348"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:38:28.071926+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BiomX Q3 net loss $6.8M; BX004 Part 1 results expected Q1 2023, cash through mid-2024

## Summary
- Cash $41.5M as of Sep 30, 2022; cash runway through at least mid-2024.
- Net loss $6.8M vs $10M in Q3 2021; R&D expenses $3.5M (down from $6.6M) due to restructuring.
- BX004 Phase 1b/2a Part 1 results expected Q1 2023; Part 2 results Q3 2023.
- CF Foundation equity award up to $5M; second $2M tranche upon Part 1 dosing completion.
- Published Cell paper on phage proof-of-concept for inflammatory bowel disease.

## SEC filing metadata
- accession: 0001213900-22-070348
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390022070348/0001213900-22-070348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390022070348/ea168308-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-070348
- JSON: https://secwatch.observer/filing/0001213900-22-070348.json
- Plain text: https://secwatch.observer/filing/0001213900-22-070348.txt

## Key facts
- Earnings Releases
  BiomX Inc. reported the third quarter ended September 30, 2022 results: net income $6.8 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: $6.8 million
  - Result: reported results
  source text: Net loss for the third quarter of 2022 was $6.8 million, compared to $10 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390022070348/0001213900-22-070348-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.